T-DM1 show overall survival advantage as Roche/Genentech make US and EU filings
This article was originally published in Scrip
Roche and its cancer specialist unit Genentech have announced that following the demonstration of an overall survival benefit in the Phase III EMILIA study, they will file for US and EU regulatory approval of the antibody-drug conjugate T-DM1 (trastuzumab emtansine). The filing had been widely expected since the antibody-drug conjugate – developed with cytotoxic and conjugation technology developed by Waltham, Massachusetts-based Immunogen - generated impressive progression-free survival results in EMILIA. Analysts are anticipating approval as early as the first quarter of 2013.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.